Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Apr 30;51(2):757-765.
doi: 10.3906/sag-2009-75.

The platelet to lymphocyte ratio predicts overall survival better than the neutrophil to lymphocyte ratio in metastatic renal cell carcinoma

Oktay Halit Aktepe  1 , Gürkan Güner  1 , Deniz Can Güven  1 , Taha Koray Şahin  2 , Fadime Sinem Ardıç  2 , Deniz Yüce  3 , Şuayib Yalçın  1 , Mustafa Erman  3
Affiliations
Observational Study

The platelet to lymphocyte ratio predicts overall survival better than the neutrophil to lymphocyte ratio in metastatic renal cell carcinoma

Oktay Halit Aktepe et al. Turk J Med Sci. .

Abstract

Background/aim: The prognostic values of systemic inflammatory markers, neutrophil to lymphocyte ratio (NLR), and platelet to lymphocyte ratio (PLR) on overall survival (OS) of metastatic renal cell carcinoma patients (mRCC) treated with tyrosine kinase inhibitors (TKI) remain unclear. Thus, the present study aimed to investigate the prognostic impact of these markers on OS of mRCC patients.

Materials and methods: A total of 150 patients receiving TKIs were retrospectively analyzed. Progression-free survival and OS times were analyzed with the Kaplan–Meier method, and the log‐rank test was used for comparison. Univariable and multivariable Cox regression models evaluated the impact of NLR and PLR on OS of the patients. The receiver operating characteristic curve analysis determined that the optimal cut-off values of NL, and PLR in predicting OS were 2 and 204, respectively.

Results: Patient with PLR > 204 had significantly lower median OS time than those with PLR ≤ 204 (14.6 months vs. 31.6 months, P < 0.001). While the univariate analyses showed that both NLR and PLR associated with OS (NLR: P = 0.002; PLR: P < 0.001), PLR, not NLR, was an independent determinant for OS in the multivariate analyses (Hazard Ratio: 2.535, 95% CI: 1.564-4.108, P < 0.001). Additionally, the presence of brain metastases and International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic scoring system were identified as independent prognostic factors for OS (brain metastases: P = 0.040; IMDC: P < 0.001).

Conclusion: The PLR is a readily and inexpensively obtained marker, which may predict OS in patients with mRCC treated with TKIs.

Keywords: NLR; PLR; metastatic renal cell carcinoma; prognosis; tyrosine kinase inhibitors.

PubMed Disclaimer

Conflict of interest statement

All authors declare no potential conflicts of interest.

Figures

Figure 1
Figure 1
ROC curve showed that the PLR value of 204 was the optimal cut-off in predicting OS.
Figure 2
Figure 2
PLR values in IMDC subgroups.Kaplan–Meier estimates of OS in patients stratified according to IMDC risk groups.
Figure 3
Figure 3
Kaplan–Meier estimates of OS in patients stratified according to IMDC risk groups.
Figure 4
Figure 4
Kaplan-Meier estimates of OS in patients stratified according to NLR (A), and PLR (B) cut-off values.
See this image and copyright information in PMC

References

    1. Siegel RL Miller KD Jemal A Cancer Journal for Clinicians . 2016;66:7–30. - PubMed
    1. Gandaglia G Ravi P Abdollah F Abd-El A-E-RM Contemporary incidence and mortality rates of kidney cancer in the United States. Canadian Urological Association Journal . 2014;8:247–247. - PMC - PubMed
    1. Hsieh JJ Purdue MP Signoretti S Swanton C Albiges L Renal cell carcinoma. Nature Reviews Disease Primers . 2017;3:17009–17009. - PMC - PubMed
    1. Heng DY Xie W Regan MM Warren MA Golshayan AR Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted agents: results from a large, multicenter study. Journal of Clinical Oncology . 2009;27:5794–5799. - PubMed
    1. Kotecha RR Motzer RJ Voss MH Towards individualized therapy for metastatic renal cell carcinoma. Nature Reviews Clinical Oncology . 2019;16:621–633. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources